Results 211 to 220 of about 39,319 (333)

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

open access: bronze, 2015
Ajai Chari   +16 more
openalex   +1 more source

Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia [PDF]

open access: hybrid, 2017
Lotta Hansson   +7 more
openalex   +1 more source

Ibrutinib Enhances the Activity of Anti-CD20 Antibodies in an MCL Mouse Model: Effect of Drug at Clinically Relevant Concentrations on ADCC and ADCP

open access: bronze, 2015
Patrick P. Ng   +5 more
openalex   +1 more source

Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations [PDF]

open access: gold, 2017
Patrizia Mondello   +11 more
openalex   +1 more source

ATM inhibition decreases ERK activation and is synergistic with ibrutinib in primary chronic lymphocytic leukemia cells. [PDF]

open access: yesBlood Adv
Kost SEF   +9 more
europepmc   +1 more source

Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib [PDF]

open access: gold, 2017
Cecelia Miller   +22 more
openalex   +1 more source

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma

open access: green, 2016
Marco Ruella   +18 more
openalex   +1 more source

INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB‐TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH‐RISK PROGNOSTIC FACTORS [PDF]

open access: bronze, 2017
Thomas J. Kipps   +22 more
openalex   +1 more source

Home - About - Disclaimer - Privacy